Harvard research dean to lead US PhRMA's science and regulatory affairs portfolio
This article was originally published in SRA
Executive Summary
The US research-based pharmaceutical industry association, PhRMA, has appointed William Chin as the new vice-president of its science and regulatory affairs department1. Dr Chin, who is currently the executive dean for research at Harvard Medical School, will take over his new role effective 1 July and will also serve as a member of PhRMA's management committee.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.